These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11163546)

  • 21. Tardive dyskinesia as a risk factor for negative symptoms.
    Taylor SJ
    Br J Psychiatry; 1994 May; 164(5):701-2. PubMed ID: 7921732
    [No Abstract]   [Full Text] [Related]  

  • 22. Negative symptoms as a risk factor for tardive dyskinesia in schizophrenia.
    Liddle PF; Barnes TR; Speller J; Kibel D
    Br J Psychiatry; 1993 Dec; 163():776-80. PubMed ID: 7905774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity.
    Gerlach J; Korsgaard S; Clemmesen P; Lauersen AM; Magelund G; Noring U; Povlsen UJ; Bech P; Casey DE
    Acta Psychiatr Scand; 1993 Apr; 87(4):244-52. PubMed ID: 8098178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extrapyramidal motor abnormalities associated with late-life psychosis.
    Caligiuri MP; Lohr JB; Panton D; Harris MJ
    Schizophr Bull; 1993; 19(4):747-54. PubMed ID: 7905662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug.
    Li CR; Chung YC; Park TW; Yang JC; Kim KW; Lee KH; Hwang IK
    World J Biol Psychiatry; 2009; 10(4 Pt 3):919-24. PubMed ID: 19995222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tardive dyskinesia and positive symptoms of schizophrenia.
    White T; Brown KW; Woods JP
    Acta Psychiatr Scand; 1991 May; 83(5):377-9. PubMed ID: 1677232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia.
    Casey DE
    Psychiatr Clin North Am; 1993 Sep; 16(3):589-610. PubMed ID: 8105453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Movement disorders in patients treated with long-acting injectable antipsychotic drugs.
    Bransgrove LL; Kelly MW
    Am J Hosp Pharm; 1994 Apr; 51(7):895-9. PubMed ID: 7912473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients.
    Gunes A; Dahl ML; Spina E; Scordo MG
    Eur J Clin Pharmacol; 2008 May; 64(5):477-82. PubMed ID: 18205001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders.
    Bergman J; Dwolatzky T; Brettholz I; Lerner V
    J Clin Psychiatry; 2005 Jan; 66(1):107-10. PubMed ID: 15669896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment.
    Modestin J; Wehrli MV; Stephan PL; Agarwalla P
    Schizophr Res; 2008 Mar; 100(1-3):97-107. PubMed ID: 18055180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prevalence of extrapyramidal effects by neuroleptics in admitted people with schizophrenia].
    Moreno-Calvete MC
    Enferm Clin; 2013; 23(3):114-7. PubMed ID: 23755945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sorting through EPS (extrapyramidal symptoms).
    Blair DT
    Geriatr Nurs; 1991; 12(5):244-6. PubMed ID: 1687319
    [No Abstract]   [Full Text] [Related]  

  • 34. Prevalence and characteristics of subjective akathisia, objective akathisia, and mixed akathisia in chronic schizophrenic subjects.
    Kim JH; Byun HJ
    Clin Neuropharmacol; 2003; 26(6):312-6. PubMed ID: 14646611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():23-7. PubMed ID: 9766616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Movement disorders associated with neuroleptic treatment.
    Wirshing WC
    J Clin Psychiatry; 2001; 62 Suppl 21():15-8. PubMed ID: 11584982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study.
    Weiden PJ; Mann JJ; Haas G; Mattson M; Frances A
    Am J Psychiatry; 1987 Sep; 144(9):1148-53. PubMed ID: 2888321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia.
    Muscettola G; Barbato G; Pampallona S; Casiello M; Bollini P
    J Clin Psychopharmacol; 1999 Jun; 19(3):203-8. PubMed ID: 10350026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study.
    Tenback DE; van Harten PN; Slooff CJ; van Os J
    Am J Psychiatry; 2006 Aug; 163(8):1438-40. PubMed ID: 16877660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship of gender and age at onset of schizophrenia to severity of dyskinesia.
    Lindamer LA; Lohr JB; Caligiuri MP; Jeste DV
    J Neuropsychiatry Clin Neurosci; 2001; 13(3):399-402. PubMed ID: 11514648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.